Abstract
Introduction
Individuals with spinal cord injury (SCI) can experience accelerated cognitive aging. Myokines (factors released from muscle cells during contractions), such as brain-derived neurotrophic factor (BDNF), are thought to have beneficial effects on cognition. Neuromuscular electrical stimulation (NMES) was shown to elicit a large release of myokines. However, the effects of NMES on cognitive function have not been studied.
Objective
To present the study protocol for a clinical trial evaluating the effects of NMES aimed at improving cognition and BDNF.
Methods
A replicated randomized three-phases single-case experimental design (SCED) with sequential multiple baseline time series and a single-armed prospective trial will be conducted with 15 adults with chronic SCI (> 12 months after injury) above L1 neurological level undergoing 30-minute quadriceps NMES, 3 days per week for 12 weeks.
Main study endpoints
Primary endpoint is cognitive performance (assessed by a smartphone test) conducted three times per week during the baseline phase with random duration of 3 to 8 weeks, the intervention phase of 12 weeks, and the follow-up phase of 3 weeks after a no measurement rest period of 12 weeks. Secondary endpoints are changes in BDNF levels and cognitive performance measured before the baseline period, before and after intervention and after a 12 weeks follow-up.
Conclusion
This will be the first study investigating the effects of 12 weeks NMES on both cognition and BDNF levels in individuals with SCI. The SCED results provide information on individual treatment effect courses which may direct future research.
Keywords
Spinal cord injury, myokine, neuromuscular electrical stimulation, cognition, neuroplasticity, brain-derived neurotrophic factor, single case experimental design, chronic rehabilitation care
Trial registration
ClinicalTrials.gov (NCT05822297, 12/01/2023)